Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia

Sponsor
Ain Shams University (Other)
Overall Status
Completed
CT.gov ID
NCT05327088
Collaborator
(none)
64
1
2
5.9
10.8

Study Details

Study Description

Brief Summary

The aim of this study is to compare epidural dexmedetomidine vs nalbuphine added to bupivacaine in labor analgesia and determine the privilege of one over the other and to compare the effect of both analgesics after delivery.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Labor pain often causes a strong stress response in women. Recently, it is concerned by most mothers and doctors that how to effectively alleviate the pain during delivery. There is no standard treatment for labor pain. A wide range of pharmacological and non-pharmacological labor pain relief techniques are available for pregnant women . Labor analgesia, also known as painless childbirth, refers to the use of various methods to reduce maternal labor pain or make it disappear. The ideal labor analgesia should be based on maternal and child safety, and should have fast acting, good analgesic effect and less adverse reaction. Epidural block anesthesia is convenient, and has less adverse reaction and obvious effect in the commonly used analgesic methods, which is widely used in the current way of analgesia. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that has sedative, hypnotic, and analgesic effects . Nalbuphine is a synthetic agonist antagoLabor pain often causes a strong stress response in women. Recently, it is concerned by most mothers and doctors that how to effectively alleviate the pain during delivery. There is no standard treatment for labor pain. A wide range of pharmacological and non-pharmacological labor pain relief techniques are available for pregnant women . Labor analgesia, also known as painless childbirth, refers to the use of various methods to reduce maternal labor pain or make it disappear. The ideal labor analgesia should be based on maternal and child safety, and should have fast acting, good analgesic effect and less adverse reaction. Epidural block anesthesia is convenient, and has less adverse reaction and obvious effect in the commonly used analgesic methods, which is widely used in the current way of analgesia. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that has sedative, hypnotic, and analgesic effects . Nalbuphine is a synthetic agonist antagonist opioid that has the characteristics of mu-antagonist and kappa-agonist activities. Nalbuphine has gained popularity as a parenteral analgesic for intraoperative, postoperative, and obstetrical uses . The purpose of this study is to compare between the 2 drugs in decreasing labor pain. st opioid that has the characteristics of mu-antagonist and kappa-agonist activities. Nalbuphine has gained popularity as a parenteral analgesic for intraoperative, postoperative, and obstetrical uses . The purpose of this study is to compare between the 2 drugs in decreasing labor pain.

Study Design

Study Type:
Interventional
Actual Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Effect of Epidural Dexmedetomidine VS Nalbuphine for Labor Analgesia
Actual Study Start Date :
Sep 12, 2021
Actual Primary Completion Date :
Feb 12, 2022
Actual Study Completion Date :
Mar 12, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group A (Dexmedetomidine group)

a bolus dose of 11ml of 0.25% bupivacaine + 0.5μg/ml preservative free dexmedetomidine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 0.5μg/ml dexmedetomidine (1ml volume) will be given when VAS score becomes 4 or more.

Drug: Dexmedetomidine
Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
Other Names:
  • Precedex
  • Active Comparator: Group B (Nalbuphine group)

    a bolus dose of 11ml of 0.25% bupivacaine + 10mg preservative free nalbuphine (1ml volume) will be injected via the epidural catheter. For top up 5 ml of 0.25% bupivacaine + 2mg nalbuphine (1ml volume) will be given when VAS score becomes 4 or more.

    Drug: Nalbuphine
    Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
    Other Names:
  • Nalufin
  • Outcome Measures

    Primary Outcome Measures

    1. change in VAS score for pain before analgesia and every 30 minutes after analgesia [before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes)]

      The visual analog scale (VAS) is a tool widely used to measure pain. A patient is asked to indicate his/her perceived pain intensity along a 100 mm (10 cm) horizontal line, and this rating is then measured from the left edge (=VAS score). The VAS score correlates well with acute pain levels (Myles et al., 1999). Using a ruler, the score is determined by measuring the distance (cm) on the 10-cm line between the no pain anchor and the patients mark, providing a range of scores from 010. A higher score indicates greater pain intensity.

    Secondary Outcome Measures

    1. change in Heart rate before analgesia and every 30 minutes after analgesia [before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes)]

      Monitored and recorded

    2. change in arterial blood pressure before analgesia and every 30 minutes after analgesia [before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes)]

      Monitored and recorded

    3. change in SpO2 before analgesia and every 30 minutes after analgesia [before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes)]

      Monitored and recorded

    4. Duration of active phase of 1st stage of labor [from 100 minutes to 300 minutes]

      The duration of active phase of 1st stage of labor varies from one to the other

    5. Duration of 2nd stage of labor [from 30 minutes to 200 minutes]

      The duration of 2nd stage of labor varies from one to the other

    6. Duration of 3rd stage of labor [from 5 minutes to 15 minutes]

      The duration of 3rd stage of labor varies from one to the other

    7. Neonatal condition: APGAR score at 1 and 5 min after the birth [At 1 minute and 5 minutes after birth]

      to check if any of the study drugs can deteriorate the neonatal condition

    8. The adverse reactions: itching, nausea, vomiting, bradycardia and hypotension [As long as the epidural catheter is inserted (up to 360 minutes)]

      These adverse reaction can occur after administration of the interventional drugs

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    All the parturients should :
    1. Be between 21 - 40 years old

    2. ASA classification I- II

    3. Para 1-2

    4. Requesting analgesia

    5. Have a normal birth canal

    6. Be at the beginning of active phase of labor i.e. cervical dilatation of 4 cm with regular uterine contractions.

    7. The fetus should be a single full-term fetus (37- 42 weeks of gestation) with normal head position, normal development.

    Exclusion Criteria:

    Parturients

    1. Younger than 21 and older than 40 years old

    2. With contraindication of regional anesthesia

    3. With pre-existing neurological disease

    4. With history of allergy to the study drugs

    5. With cephalopelvic disproportion, fetal distress, amniotic fluid infection, placental insufficiency or scarred uterus

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ain Shams University Cairo Egypt

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Nourhan Tarek, Principal Investigator, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05327088
    Other Study ID Numbers:
    • Epidural analgesia
    First Posted:
    Apr 14, 2022
    Last Update Posted:
    Apr 14, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Nourhan Tarek, Principal Investigator, Ain Shams University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 14, 2022